Immunotoxin treatment of cancer
- PMID: 17059365
- DOI: 10.1146/annurev.med.58.070605.115320
Immunotoxin treatment of cancer
Abstract
Immunotoxins are proteins used to treat cancer that are composed of an antibody fragment linked to a toxin. The immunotoxin binds to a surface antigen on a cancer cell, enters the cell by endocytosis, and kills it. The most potent immunotoxins are made from bacterial and plant toxins. Refinements over many years have produced recombinant immunotoxins; these therapeutic proteins are made using protein engineering. Individual immunotoxins are designed to treat specific cancers. To date, most success has been achieved treating hematologic tumors. Obstacles to successful treatment of solid tumors include poor penetration into tumor masses and the immune response to the toxin component of the immunotoxin, which limits the number of cycles that can be given. Strategies to overcome these limitations are being pursued.
Similar articles
-
Targeted toxins in brain tumor therapy.Toxins (Basel). 2010 Nov;2(11):2645-62. doi: 10.3390/toxins2112645. Epub 2010 Nov 1. Toxins (Basel). 2010. PMID: 22069569 Free PMC article. Review.
-
Recombinant antibody fragments and immunotoxin fusions for cancer therapy.In Vivo. 2000 Jan-Feb;14(1):21-7. In Vivo. 2000. PMID: 10757057 Review.
-
Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids.Biotechnol Bioeng. 1999 Mar 5;62(5):562-75. Biotechnol Bioeng. 1999. PMID: 10099565
-
Therapeutic use of immunotoxins.Semin Hematol. 1992 Jul;29(3 Suppl 2):6-13. Semin Hematol. 1992. PMID: 1509295 Review.
-
Therapeutic potential of anticancer immunotoxins.Drug Discov Today. 2011 Jun;16(11-12):495-503. doi: 10.1016/j.drudis.2011.04.003. Epub 2011 Apr 12. Drug Discov Today. 2011. PMID: 21511052 Review.
Cited by
-
Targeting of interleukin-13 receptor α2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF-β and PTEN signaling.J Transl Med. 2013 Feb 19;11:45. doi: 10.1186/1479-5876-11-45. J Transl Med. 2013. PMID: 23421960 Free PMC article.
-
Targeting tumor resistance mechanisms.Fac Rev. 2021 Jan 26;10:6. doi: 10.12703/r/10-6. eCollection 2021. Fac Rev. 2021. PMID: 33659924 Free PMC article. Review.
-
Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition.Mol Ther Nucleic Acids. 2012 Oct 16;1(10):e51. doi: 10.1038/mtna.2012.41. Mol Ther Nucleic Acids. 2012. PMID: 23344651 Free PMC article.
-
Use of a Novel Integrase-Deficient Lentivirus for Targeted Anti-Cancer Therapy With Survivin Promoter-Driven Diphtheria Toxin A.Medicine (Baltimore). 2015 Aug;94(31):e1301. doi: 10.1097/MD.0000000000001301. Medicine (Baltimore). 2015. PMID: 26252309 Free PMC article.
-
Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38.Mol Cancer Ther. 2010 Apr;9(4):1039-46. doi: 10.1158/1535-7163.MCT-09-0996. Epub 2010 Apr 6. Mol Cancer Ther. 2010. PMID: 20371725 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources